More Patients Relapse in Gilead Hepatitis C Trial

Two more patients in a 10-patient segment of a mid-stage trial testing Gilead Sciences’ experimental hepatitis C drug GS-7977 had the virus return within four weeks of treatment.
Chicago Tribune